Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Published:2019-02-08 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Papachristofilou Alexandros,Hipp Madeleine M.,Klinkhardt Ute,Früh Martin,Sebastian Martin,Weiss Christian,Pless Miklos,Cathomas Richard,Hilbe Wolfgang,Pall Georg,Wehler Thomas,Alt Jürgen,Bischoff Helge,Geißler Michael,Griesinger Frank,Kallen Karl-Josef,Fotin-Mleczek Mariola,Schröder Andreas,Scheel Birgit,Muth Anke,Seibel Tobias,Stosnach Claudia,Doener Fatma,Hong Henoch S.,Koch Sven D.,Gnad-Vogt Ulrike,Zippelius Alfred

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0520-5.pdf

Reference46 articles.

1. Socola F, Scherfenberg N, Raez LE. Therapeutic vaccines in non-small cell lung cancer. Immunotargets Ther. 2013;2:115–24.

2. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59–68.

3. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822–35.

4. Berraondo P, Umansky V, Melero I. Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res. 2012;72:5159–64.

5. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30:1–7.

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the design and delivery of RNA vaccines for infectious diseases;Advanced Drug Delivery Reviews;2024-10

2. Advances and prospects of RNA delivery nanoplatforms for cancer therapy;Acta Pharmaceutica Sinica B;2024-09

3. The progress of tumor vaccines clinical trials in non-small cell lung cancer;Clinical and Translational Oncology;2024-08-23

4. The current therapeutic cancer vaccines landscape in non‐small cell lung cancer;International Journal of Cancer;2024-08-07

5. Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade;Materials Today Bio;2024-08